Advanced Search

 

Study ID Status Title Patient Level Data
AVA102677 Terminated An open-label extension to study AVA105640, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease. Study Listed on ClinicalStudyDataRequest.com
AVA104617 Completed An open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease Study Listed on ClinicalStudyDataRequest.com
AVA109941 Completed An open label single oral dose study in patients with mild Alzheimer's disease to assess the pharmacokinetics of extended release formulation of Rosiglitazone (RSG XR) in this population
AVD100521 Completed A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH) Study Listed on ClinicalStudyDataRequest.com
AVD104742 Completed Clinical evaluation of Rosiglitazone Malate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo - Study Listed on ClinicalStudyDataRequest.com
AVD105248 Completed Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients with Type 2 Diabetes Mellitus (Combination Therapy with Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study - Study Listed on ClinicalStudyDataRequest.com
AVD105720 Completed Clinical evaluation of Rosiglitazone Malate (BRL49653C) in patients with type 2 diabetes mellitus -Long-term study of Rosiglitazone Maleate- Study Listed on ClinicalStudyDataRequest.com
AVD111179 Completed A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
AVO105948 Completed A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management Study Listed on ClinicalStudyDataRequest.com
AVO108943 Completed A Randomized Double-Blind Parallel Group Study Comparing Casodex (or generic equivalent) 50mg plus Placebo to Casodex (or generic equivalent) 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Study Listed on ClinicalStudyDataRequest.com
AVS101946 Completed A 16 week randomized, double-blind, parallel group study to evaluate the efficacy and safety of a new medication (GSK523338) to lower LDL-c and HbA1c in subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
AVT105913 Completed A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment. Study Listed on ClinicalStudyDataRequest.com
AXO110461 Completed A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating single dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered SB756050 in healthy volunteers and in subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
B2B10001 Completed A randomised, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of GW678007 in healthy male subjects. Study Listed on ClinicalStudyDataRequest.com
B2C10001 Completed A randomised, double blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and systemic pharmacokinetic profile of single inhaled doses of GW642444 in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
B2C101762 Completed A multi-centre, randomised, double-blind, placebo controlled, dose ascending, four way crossover study to examine efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444 Study Listed on ClinicalStudyDataRequest.com
B2C104604 Completed A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M Study Listed on ClinicalStudyDataRequest.com
B2C106093 Completed Multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 mcg once daily) of GW642444 Study Listed on ClinicalStudyDataRequest.com
B2C106180 Completed A single-centre, open-label, sequential, dose-ascending study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of single intravenous, inhaled and oral doses of GW642444 in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
B2C106996 Completed A randomized, single-dose, dose-ascending, double blind, placebo-controlled, 5-way crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in asthmatic patients Study Listed on ClinicalStudyDataRequest.com
B2C108562 Completed A 2-wk study to evaluate the safety, tolerability,pharmacodynamics and pharmacokinetics of GW642444H(100 administered once daily in the morning via DISKUS™ dry-powder inhaler)compared with SEREVENT(salmeterol)(50mcg administered twice daily via DISKUS dry-powder inhaler)and placebo in subject w/COPD Study Listed on ClinicalStudyDataRequest.com
B2C108784 Completed A randomised, double-blind, placebo-controlled, parallel-group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and extra-pulmonary pharmacodynamics of inhaled doses of GW642444M formulated with magnesium stearate in healthy subjects Study Listed on ClinicalStudyDataRequest.com
B2C109575 Completed A randomised, double-blind, placebo controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma Study Listed on ClinicalStudyDataRequest.com
B2C110165 Completed A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients. Study Listed on ClinicalStudyDataRequest.com
B2C111045 Completed Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.